DELRAY BEACH, FL - January 30, 2012 (Investorideas.com Newswire) Medical Stock Alert; PositiveID Corporation (OTCBB: PSID), a developer of medical technologies for diabetes management, announced today it has obtained certification from AT&T for PositiveID's iglucose™ mobile health system, designed to simplify diabetes management for the millions of individuals impacted by this growing disease. This certification gives PositiveID's FDA-cleared iglucose system access to the AT&T network, which has the largest global presence of any U.S.-based wireless provider.
iglucose is the first and only pocket sized, FDA cleared, mobile health device specifically designed to connect to industry leading glucometers to transmit blood glucose readings anytime, anywhere. By seamlessly communicating glucose readings from a glucometer to the iglucose diabetes management portal, this important data can be shared with family members, caregivers and healthcare professionals via text message, email or fax, or through the iglucose diabetes management portal itself. iglucose makes it easier for individuals with diabetes to manage their disease and provides healthcare professionals with better data that can be used to improve clinical insight and treatment decisions.
Laboratory testing for the iglucose device was conducted in AT&T's wireless device testing laboratory. During certification, AT&T subjects each device to a series of rigorous tests to ensure the operational reliability of each unit as well as its ability to function flawlessly across the entire AT&T wireless network. iglucose is specifically designed for mobile monitoring, which helped to ensure optimum performance of the device during testing.
While medical devices for home monitoring have existed for many years, the devices are typically large, expensive and not targeted solely for the diabetes population. iglucose was designed with the end user in mind; the iglucose device fits easily into the pouch individuals with diabetes typically carry containing their blood glucose meter and test strips. Furthermore, because iglucose does not require a phone line or internet connection, its portability and compact size mean it can be used anywhere, anytime.
The iglucose system is compatible with market-leading glucometers such as Johnson & Johnson LifeScan®, Nipro Diagnostic™ True™, Abbott Freestyle®, and Bayer Breeze® and Contour® meters.
PositiveID Chairman and CEO William J. Caragol, said, "AT&T certification, which is not easily achieved, is an important confirmation of the performance and dependability of iglucose . As we continue to prepare to roll-out this mobile health system early this year through pilot programs with insurers and home-healthcare providers, AT&T certification provides us significant validation upon which our customers and partners can rely."
More than 25 million children and adults in the U.S. have diabetes, or over eight percent of the population, according to the 2011 National Diabetes Fact Sheet . The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at $200 billion.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit http://www.PositiveIDCorp.com .
For more information on iglucose, please visit http://www.iglucose.com . For sales and partnership opportunities, please contact Mary Ellen Harrison at 561-805-8028 or meharrison@positiveidcorp.com.
Statements about PositiveID's future expectations, including the likelihood that AT&T certification gives PositiveID's FDA-cleared iglucose system access to the AT&T network, which has the largest global presence of any U.S.-based wireless provider; the likelihood that iglucose makes it easier for individuals with diabetes to manage their disease and provides healthcare professionals with better data that can be used to improve clinical insight and treatment decisions; the likelihood that because iglucose does not require a phone line or internet connection, its portability and compact size mean it can be used anywhere, anytime; the likelihood the iglucose system is compatible with market-leading glucometers such as Johnson & Johnson LifeScan, Nipro Diagnostic True, Abbott Freestyle, and Bayer Breeze and Contour meters; the likelihood that AT&T certification, which is not easily achieved, is an important confirmation of the performance and dependability of iglucose; the likelihood that as PositiveID continues to prepare to roll-out this mobile health system early this year through pilot programs with insurers and home-healthcare providers, AT&T certification provides PositiveID significant validation upon which its customers and partners can rely; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Published at the Investorideas.com Newswire and syndicated blogs
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation ( OTCBB:PSID ) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
No comments:
Post a Comment